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1. Introduction
Dilated  cardiomyopathy  (DCM)  is  one  of  the  most  common  types  of  cardiomyopathy
worldwide.  It  is  characterized by progressive chamber dilatation and myocardial  systolic
dysfunction  and  diagnosed  by  finding  left  ventricular  (LV)  enlargement  and  impaired
systolic  LV function  (LV ejection  fraction  less  than 50% or  fractional  shortening  of  less
than 25-30%).  Angiotensin-converting enzyme inhibitors  and ß-blockers  are the best  and
popular  therapeutic  interventions  for  DCM  that  promotes  amelioration  of  systolic  LV
dysfunction  among 20-45% DCM patients  [1  -  5];  nonetheless,  the  5-year  mortality  rate
of  DCM remains 10-35% under these medical  therapy [6  -  8].
The  predictive  assessment  of  LV  function  is  clinically  important  in  medical  manage‐
ment of  DCM, particularly when considering the indication for  heart  transplantation.  In
most  patients  with  heart  failure,  symptoms are  not  present  at  rest  but  become limiting
with  exercise.  Nevertheless,  the  major  measures  for  LV  function  of  DCM,  such  as
echocardiography,  are  generally  performed  under  the  static  condition.  In  addition,  LV
contractile  function  at  rest  is  not  reliable  for  an  assessment  of  the  reversibility  of  LV
contraction,  that  is  contractile  reserve  [3,  4].  Therefore,  it  is  important  to  evaluate  LV
functional  response  under  dynamic  conditions  by  use  of  pharmacological  as  well  as
exercise  stress  [9].
This  article  reviews the current status of  myocardial  contractile  reserve with our findings,
including  procedures  for  evaluating  contractile  reserve,  clinical  implications,  and
molecular  biological  significance.
© 2013 Okumura and Murohara; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Contractile reserve in DCM
2.1. Myocardial contractile reserve
Myocardial contractile reserve measured by stress testing has been defined as a difference LV
function at rest and under load. To date, the assessment of myocardial contractile reserve
limitedly applied to evaluate the myocardial viability exclusively in patients with LV dys‐
function and coronary artery disease. Nowadays, glowing evidences suggest the clinical
importance to evaluating the contractile reserve in non-ischemic DCM [9, 10]. In particular to
the case of DCM, the assessment of myocardial contractile reserve is mainly focused to evaluate
the presence of residual LV contractile reserve.
2.2. Pathophysiological implications
Determinant factors of myocardial contractile reserve include the Frank-Starling mechanism,
the force-frequency effect, and adrenergic stimulation [11, 12]. In DCM patients, myocardial
contractile reserve to adrenergic stimulation is impaired [9].
Myocardial contractile reserve by stress testing provide important prognostic information in
DCM [13]. Previous studies reported that patients exhibiting load-induced enhancement of
systolic LV function had better clinical outcomes [10, 14 - 17] and LV contractile reserve is a
useful marker to predict future LV functional improvement in the treatment of beta blocker
or after cardiac resynchrnonization therapy [18 - 21].
In addition, myocardial contractile reserve is associated with other prognostic biomarkers and
molecule expressions in cardiomyocyte. Firstly, LV inotropic reserve is associated with
exercise capacity [14]. The contractile reserve correlates with peak oxygen consumption (peak
VO2) in cardiopulmonary exercise testing [22, 23]. Moreover, patients with greater increase in
myocardial contractile reserve achieved a greater peak VO2 [23]. Secondly, impaired LV
contractile reserve was reported to be associated with cardiac sympathetic dysfunction
measured by myocardial iodine-123-metaiodobenzylgluanidine (123I-MIBG) scintigraphy [24].
Finally, we reported that reduced adrenergic myocardial contractile reserve related to
myocardial expression of contractile regulatory protein mRNAs, such as beta1-adrenergic
receptor, sarcoplasmic reticulum Ca2+-adrenergic triphosphatase, and phospholamban [25].
Moreover, the assessment of LV response using a stress testing may also help in the screening
or monitoring the presence of latent myocardial dysfunction in patients with the initial phase
of cardiomyopathy overt normal resting echocardiographic parameters who had exposure to
cardiotoxic agents [26].
3. How to evaluate contractile reserve?
Myocardial contractile reserve is usually defined as a difference between LV function at rest
and under load. LV function has been evaluated by a variety of modalities, such as echocar‐
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diography, cardiac pool scintigraphy, and cardiac catheterization. Exercise and inotropic stress
have been used as stress protocols for the assessment of contractile reserve. Both stresses
provoke a generalized increase of regional wall motion with an increment of ejection fraction
[27]. Although regional LV wall dysfunction is commonly caused by coronary artery ischemia,
regional wall motion abnormality is sometimes shown in non-ischemic cardiomyopathy [28].
The selection of evaluation method and stress modality mainly depends on the patient’s
exercise capacity, the purpose of the examination, and medical contraindications.
3.1. Exercise stress
Exercise stress is a very useful and the best physiological stressor. Therefore, exercise testing
should be performed in patients who are physically allowed [27]. Images can be obtained by
use of pre- and within one minute of post- treadmill, upright or supine cycle exercise. However,
the weakness of stress echocardiography is that it depends on image quality and its use by the
occasional user may be attached with loss of accuracy.
3.2. Dobutamine stress
Pharmacologic stress testing is preferred for patients unable to exercise. Use of low dose
dobutamine seems to be the best stress method for the assessment of myocardial contractile
reserve, unless there is a contraindication [29]. The protocol of dobutamine infusions vary from
investigators, but the patient usually undergo the stress testing using standardised incremental
infusions of 5, 10, and 20 µg/kg/min [30]. The safety dose has been documented as high as 40
µg/kg/min and serious complications occurs in about 0.3 %.
3.3. Interpretension
In stress echocardiography, global LV function at rest is assessed by calculation of ejection
fraction or wall motion score index on the resting images. After collecting stress images, both
data are compared for the development of global function. As for the evaluation of regional
function, regional wall motion scoring is generally used. Generally, the critical level to define
the presence of contractile reserve is defined as an increase of more than 5% in the global LV
ejection fraction [31].
Some studies have evaluated the adrenergic contractile reserve by measurement of increase
in the maximal first derivative of LV pressure (LV dP/dtmax) using a cardiac catheter in patients
with non-ischemic LV dysfunction [15, 32].
3.4. Stress testing protocol in our studies
Our protocol for the evaluation of myocardial contractile reserve consists of low-dose dobut‐
amine infusion and cardiac catheterization (Figure 1). Although a lot of investigations which
reported dobutamine stress testing were measured by echocardiography, we more accurately
evaluate LV response using catheterization with a high-fidelity micromanometer.
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Initially, routine diagnostic left and right heart catheterization are performed. A 6-F fluid-filled
pigtail catheter with a high-fidelity micromanometer (CA-61000-PLB Pressure-tip Catheter,
CD Leycom, Zoetermeer, The Netherlands) is placed in the LV cavity for measurement of LV
pressure. We evaluate LV dP/dtmax as an index of LV contractility [33]. After collection of
baseline hemodynamic data, dobutamine is infused intravenously at incremental doses of 5,
10, and 15 µg/kg/min and hemodynamic measurements are made at the end of each 5-minute
infusion period. In addition, we calculate ΔLV dP/dtmax as an index of myocardial contractile
reserve [25]. ΔLV dP/dtmax is defined as the percentage increase in LV dP/dtmax induced by
dobutamine, and this index is defined on the basis of the formula.
ΔLV dP/dtmax(x) = LV dP/dtmax(x) - LV dP/dtmax(baseline) / LV dP/dtmax(baseline)
where x = the dose of dobutamine (µg/kg/min)
Figure 1. Protocol for evaluating myocardial contractile reserve in DCM
4. Clinical implications of myocardial contractile reserve
4.1. Exercise capacity and contractile reserve
The presence of LV inotropic response during dobutamine stress testing is associated with a
better performance [14]. Patients with markedly reduced myocardial contractility at rest, but
with good residual contractile reserve, have a favorable exercise capacity. On the other hand,
patients with mildly abnormal myocardial contractility at rest, but reduced contractile reserve
have a poor capacity [34].
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Recently, we reported the association between myocardial contractile reserve and exercise
capacity in 38 idiopathic DCM patients [23]. Peak VO2 was significantly correlated with ΔLV
dP/dtmax, but not with LV dP/dtmax at baseline. In addition, the correlation became more
pronounced as the dose of dobutamine was increased (Figure 2). Multivariate regression
analysis revealed that ΔLV dP/dtmax was independently correlated with peak VO2 (p=0.011).
There was no correlation between minute ventilation/carbon dioxide production (VE/VCO2)
slope and ΔLV dP/dtmax.
ΔLV dP/dtmax was significantly correlated with peak VO2, and the correlation became more pronounced as the dose of
dobutamine was increased. In contrast, no significant inverse correlation between ΔLV dP/dtmax and VE/VCO2 slope
was apparent, even at the maximum dose of dobutamine. ΔLV dP/dtmax is the percentage increase in LV dP/dtmax in‐
duced by dobutamine. [23]
Figure 2. Correlation between myocardial contractile reserve and peak VO2, VE/VCO2 slope.
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Paraskevaidis, et al. reported the utility of evaluating the presence of myocardial contractile
reserve in patients with intermediate values of peak VO2 (10-14 mL/kg/min) [35]. They conclud‐
ed that contractile reserve may yield the greatest incremental prognostic value in gray zone
candidates for cardiac transplantation and provide further information for the risk stratification.
These results suggested that myocardial contractile reserve can be used as an adjunct or an
alternative to predict peak VO2 in patients with heart failure, especially when the patients fall
into the gray zone of peak VO2 or when the patients have a difficulty in ambulation.
4.2. Cardiac sympathetic function and contractile reserve
In 2005, we reported the correlation of impaired contractile reserve with cardiac sympathetic
dysfunction in 24 DCM patients [24]. A significant correlation was observed between the
delayed 123I-MIBG heart-mediastinum ratio (HMR) and the percentage change in LV dP/
dtmax from the baseline to the peak heart rate (Figure 3). The delayed 123I-MIBG HMR was
significantly lower in patients with a worsening change in LV dP/dtmax (p=0.004). As for the
expression of mRNA, there is no significant difference in abundance for sarcoplasmic reticu‐
lum Ca2+-ATPase (SERCA2). However, SERCA2/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) ratio was significantly lower in low HMR group, indicating that reduced expression
of SERCA2 is associated with impaired cardiac sympathetic activity.
Figure 3. Relationship between the delayed 123I-MIBG HMR and the percentage change in LV dP/dtmax from the base‐
line to the peak or critical heart rate. (modified from [24])
This result indicated that the myocardial 123I-MIBG scintigraphy may reflect myocardial con‐
tractile reserve, and may be useful in non-invasively predicting residual contractile reserve.
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4.3. Prognosis and contractile reserve
LV contractility has been considered to be the most powerful predictor of prognosis in DCM.
Around 2000, an array of studies reported the association between LV contractile reserve and
prognosis, and the presence of contractile reserve came to be considered as the most powerful
prognostic predictor [10, 14 - 17].
We investigated the contractile reserve during dobutamine infusion in relation to the prognosis
in 52 patients with mildly symptomatic DCM. In the ΔLV dP/dtmax(10) <60% group, cardiac
events were significantly higher than in the ΔLV dP/dtmax(10) ≥60% group. Peak VO2 <18 (mL/
kg/min) (HR:3.18, p=0.029) and ∆LV dP/dtmax(10) <60% (HR:3.25, p=0.026) were comparable
predictors of cardiac events (Figure 4). This result indicated that evaluating the myocardial
contractile reserve in dobutamine stress testing and peak VO2 in cardiopulmonary exercise
testing may be complementary approaches to predict a prognosis of non-ischemic DCM.
 
In the peak VO2 <18 (mL/kg/min) group, cardiac events were significantly higher than in the peak VO2 ≥18 group. In
addition, cardiac events were significantly higher in the ΔLV dP/dtmax(10) <60% group than in the ΔLV dP/dtmax(10)
≥60% group. Peak VO2 <18 (HR:3.18, p=0.029) and ∆LV dP/dtmax(10) <60% (HR:3.25, p=0.026) were comparable pre‐
dictors of cardiac events.
Figure 4. Kaplan-Meier analysis of cardiac event-free survival in 52 DCM patients.
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Kasama S, et al. evaluated the LV response using dobutamine gated blood pool scintigraphy
in 22 DCM patients [20]. In the good response group to 15 µg/kg/min dobutamine (the presence
of contractile reserve; echocardiographic LV ejection fraction >5% improvement), LV systolic
function was significantly improved after 1 year of ß-blocker therapy. Cardiac sympathetic
nerve activity and New York Heart Association functional class also improved with cardiac
reverse remodeling. In addition, they investigated contractile reserve using 99mTc-tetrofosmin
quantitative gated single photon emission computed tomography (SPECT) and the similar
findings were shown [21].
4.4. Molecular biological significance and contractile reserve
Recently, we reported that dobutamine stress testing is a useful diagnostic tool for evaluating
adrenergic myocardial contractile reserve. This residual contractile reserve is related to alterd
myocardial expression of ß1-adrenergic receptor, SERCA2a, and phospholamban genes in
DCM [25]. In this study, 46 asymptomatic or mildly-symptomatic DCM patients were enrolled
and classified into 3 groups based on baseline LV ejection fraction and ΔLV dP/dtmax (Figure
5). The amounts of ß1-adrenergic receptor, SERCA2a, and phospholamban mRNA were
significantly smaller in group IIa and IIb than in group I (Table 1). This result indicated that
impaired contractile reserve by dobutamine stress testing may be associated with molecular
remodeling caused by the overactivation of sympathetic nerve system.
Patients were classified into 3 groups: group I (orange with black circles), ∆LV dP/dtmax >100% (LV ejection fraction
[LVEF] >25%); group IIa (orange circles), ∆LV dP/dtmax ≤100% and LVEF >25%; and group IIb (brown triangles), ∆LV
dP/dtmax ≤100% and LVEF ≤25%. [25]
Figure 5. Relation between baseline LV ejection fraction and LV dP/dtmax
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mRNA Group I Group IIa Group IIb
Beta1-AR 1.39 ± 0.68 0.71 ± 0.19* 0.66 ± 0.29*
Beta2-AR 1.29 ± 0.92 0.95 ± 0.18 0.91 ± 0.40
GRK2 1.54 ± 0.63 1.53 ± 0.26 1.59 ± 0.58
G5 alpha 1.18 ± 0.40 0.94 ± 0.17 1.04 ± 0.34
Gi2 alpha 0.78 ± 0.35 0.77 ± 0.15 0.85 ± 0.25
SERCA2a 0.60 ± 0.29 0.36 ± 0.08* 0.37 ± 0.12*
Phospholamban 0.82 ± 0.28 0.56 ± 0.12* 0.36 ± 0.16*
Ryanodine receptor-2 0.74 ± 0.42 0.56 ± 0.17 0.69 ± 0.23
Calsequestrin 1.34 ± 0.58 1.16 ± 0.25 1.30 ± 0.44
Na+/Ca2+ exchanger 1.69 ± 0.76 1.14 ± 0.14 1.46 ± 0.84
Data are means ± SD. *p <0.05 vs. group I.
AR = adrenergic receptor; GRK2 = G protein-coupled receptor kinase 2; mRNA
= messenger ribonucleic acid; SERCA2a = sarcoplasmic reticulum Ca2+ adenosine
triphosphatase 2a.
Data are means ± SD. * p<0.05 vs. group I.
AR= adrenergic receptor, GRK2+ G protein-coupled receptor kinase 2; mRNA = messenger ribonucleic acid; SERCA 2a =
sarcoplasmic reticulum Ca2+ adenosine triphosphate 2a.
Table 1. Relative Abundance of Contractile Regulatory Protein mRNAs in Endomyocardial Biopsy Specimens Relative
to the Corresponding Amount of Glyceraldehyde-3-Phosphate Dehydrogenase mRNA [25]
4.5. Latest findings about contractile reserve
At present, it is reported that the patients with non-ischemic DCM have an impairment of
coronary microcirculation and their coronary flow reserve is diminished [36, 37]. Skalidis EI,
et al. investigated the association between LV contractile reserve and coronary flow reserve
[38]. They studied 14 patients with idiopathic DCM and 11 control subjects. A significant
correlation between coronary flow reserve and the corresponding contractile reserve in the
vascular territory was reported. Interstingly, Otasevic P, et al. reported the relation of myo‐
cardial histomorphometric features in endomyocardial biopsy specimens and LV contractile
reserve assessed by dobutamine stress echocardiography [39]. It was revealed that myocyte
diameter and interstitial fibrosis strongly correlated with change in the wall motion score
index, followed by the change in LV ejection fraction. Recently, Yamada S, et al. invetigated
the association between myocardial blood volume and LV contractile reserve in 21 DCM
patients using myocardial contrast echocardiography [40]. Myocardial blood volume was not
correlated with any parameters of resting LV function, but significantly correlated with percent
increase in LV ejection fraction during dobutamine stress testing. They speculated in their
paper that myocardial histomorphometric features in DCM conceivably cause the reduction
in myocardial blood volume, being related to the depressed contractile reserve.
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5. Conclusions and future perspectives
As present, stress testing, especially by dobutamine infusion, is considered to be useful for
detecting residual contractile reserve in DCM. Myocardial contractile reserve is usually
detected by echocardiography, but sometimes evaluated by other modalities for accuracy, such
as quantitative gated SPECT, cardiac pool scintigraphy, and LV pressure analysis. A lot of
previous studies revealed that the presence of residual contractile reserve is associated with a
good prognosis and impaired contractile reserve is affected by multiple factors including, but
not limited to, exercise intolerance, cardiac sympathetic dysfunction, reduced myocardial
blood flow and histopathological changes. In addition, the possibility is suggested that
myocardial contractile reserve would predict a reversibility of LV dysfunction after initiation
of cardioprotective therapy. Evaluating residual contractile reserve may have key information
to predict response to interventional therapy. Therefore, further studies are required in order
to detect non-responders with no available future reverse remodeling.
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